Results 171 to 180 of about 123,231 (223)
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Leukotriene-receptor antagonists
Lancet, The, 1999Leukotriene-receptor antagonists are the first novel class of antiasthma drugs to become available over the past three decades. They have an unique profile in that they are a hybrid of an anti-inflammatory and bronchodilator drug, and they can be taken as a tablet once or twice daily.
Brian Lipworth
exaly +5 more sources
Leukotriene antagonists and synthesis inhibitors: New directions in asthma therapy
Journal of Allergy and Clinical Immunology, 1996 This article briefly reviews the advances in our understanding of asthma with a particular focus on the role of inflammation, before providing a concise overview of current knowledge of leukotrienes in the pathophysiology of the disease.
Peter Bradding +2 more
exaly +2 more sources
Clinics in Liver Disease, 2003
Hepatotoxicity is the most common cause of fulminant hepatic failure in the United States and the main indication for market withdrawal of drugs. This condition has been increasingly recognized as a problem of enormous medical, financial legal, and regulatory importance.
Timothy J, Davern, Nathan M, Bass
openaire +2 more sources
Hepatotoxicity is the most common cause of fulminant hepatic failure in the United States and the main indication for market withdrawal of drugs. This condition has been increasingly recognized as a problem of enormous medical, financial legal, and regulatory importance.
Timothy J, Davern, Nathan M, Bass
openaire +2 more sources
Leukotriene Antagonists in Asthma
New England Journal of Medicine, 2011Aim Cysteinyl leukotrienes are important pro-inflammatory mediators in the pathogenesis of asthma, while leukotriene C 4 synthase is a key enzyme in their biosynthesis. Our aim is to evaluate whether responsiveness to leukotriene receptor antagonists was determined by expression of the variant (C) or wild-type (A) polymorphism of this enzyme.
Lipworth, Brian, Jackson, Catherine
openaire +5 more sources
Leukotriene and thromboxane antagonists
Clinical Reviews in Allergy, 1994It has been suggested that arachidonate metabolites, leukotrienes, and thromboxane may play important roles in the pathogenesis of bronchial asthma. Biologic activities of these mediators are much more potent than those of histamine and acetylcholine on a molar basis in inducing bronchoconstriction, increase in microvascular permeability, formation of ...
T, Obata, N, Yamashita, T, Nakagawa
openaire +2 more sources
Journal of Allergy and Clinical Immunology, 2006 Background: Leukotriene (LT) E(4) and 8-isoprostane concentrations are elevated in exhaled breath condensate in children with asthma. The effects of leukotriene receptor antagonists (LTRAs) on exhaled leukotriene and prostanoids in children with asthma ...
Paolo Montuschi +2 more
exaly +1 more source
Leukotriene receptor antagonists - an update
Drug and Therapeutics Bulletin, 2005Montelukast (Singulair - MSD) and zafirlukast (Accolate - AstraZeneca) are oral leukotriene receptor antagonists, licensed for the treatment of patients with asthma. In 1998, soon after their launch, we concluded that there was insufficient evidence to clearly define their place in treatment.1 Here, we reconsider their role in adults and children with ...
openaire +2 more sources
Pharmacology of Leukotriene Receptor Antagonists
American Journal of Respiratory and Critical Care Medicine, 1998Abstract Preclinical pharmacological studies have demonstrated that cysLT1 receptor antagonists, such as zafirlukast, montelukast, and pobilukast, are potent and selective antagonists of cysteinyl leukotriene (cysLT) activity. In vitro, these agents compete with [3H]LTD4 for binding to cysLT1 receptors present on guinea pig and human ...
openaire +2 more sources